Pfizer’s Humira biosimilar hits efficacy target – PharmaTimes

Pfizer has reported positive results from a trial of its monoclonal antibody PF-06410293, which the firm is developing as a biosimilar of AbbVie’s blockbuster Humira.The drug giant said the REFLECTIONS B538-02 study met its primary endpoint by demonstrating that the therapy’s efficacy was equivalent to Humira (adalimumab) – as measured by the American College of Rheumatology 20 (ACR20) response rate at Week 12 – in patients with moderate to severe rheumatoid arthritis.PF-06410293 is the second proposed inflammation biosimilar and the third proposed biosimilar pipeline molecule to report positive top-line results within the past four months, Pfizer noted.Humira, an anti-TNF monoclonal antibody, pulls in annual sales of nearly $15 billion across its range of indications for inflammatory diseases.

Read The Full Source: Pfizer’s Humira biosimilar hits efficacy target – PharmaTimes


Leave a reply

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2019  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Log in with your credentials

Forgot your details?